8.30
Precedente Chiudi:
$8.39
Aprire:
$8.42
Volume 24 ore:
682.85K
Relative Volume:
0.48
Capitalizzazione di mercato:
$739.87M
Reddito:
$380.79M
Utile/perdita netta:
$49.27M
Rapporto P/E:
11.86
EPS:
0.7
Flusso di cassa netto:
$10.68M
1 W Prestazione:
+0.24%
1M Prestazione:
+29.49%
6M Prestazione:
+130.56%
1 anno Prestazione:
+332.29%
Amylyx Pharmaceuticals Inc Stock (AMLX) Company Profile
Nome
Amylyx Pharmaceuticals Inc
Settore
Industria
Telefono
617-683-0917
Indirizzo
43 THORNDIKE STREET, CAMBRIDGE
Confronta AMLX con altri titoli
Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
---|---|---|---|---|---|---|
![]()
AMLX
Amylyx Pharmaceuticals Inc
|
8.30 | 701.54M | 380.79M | 49.27M | 10.68M | 0.70 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
472.27 | 120.73B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
564.64 | 61.80B | 14.09B | 4.50B | 2.96B | 39.28 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
328.00 | 42.46B | 2.35B | -269.70M | -75.39M | -2.09 |
![]()
ARGX
Argen X Se Adr
|
591.74 | 35.22B | 2.58B | 1.06B | -1.28B | 16.33 |
![]()
ONC
Beone Medicines Ltd Adr
|
296.46 | 31.99B | 3.81B | -644.79M | -669.77M | -6.24 |
Amylyx Pharmaceuticals Inc Stock (AMLX) Upgrades & Downgrades
Data | Azione | Analista | Modifica della valutazione |
---|---|---|---|
2025-07-10 | Ripresa | Goldman | Buy |
2025-06-24 | Iniziato | Guggenheim | Buy |
2025-06-17 | Iniziato | Citigroup | Buy |
2025-05-30 | Iniziato | TD Cowen | Buy |
2025-04-07 | Aggiornamento | Mizuho | Neutral → Outperform |
2024-11-18 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
2024-10-23 | Aggiornamento | BofA Securities | Neutral → Buy |
2024-03-18 | Downgrade | Mizuho | Buy → Neutral |
2024-03-11 | Downgrade | Leerink Partners | Outperform → Market Perform |
2024-03-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
2024-03-08 | Downgrade | Evercore ISI | Outperform → In-line |
2024-03-08 | Downgrade | Goldman | Buy → Neutral |
2024-01-03 | Iniziato | Robert W. Baird | Outperform |
2023-12-12 | Iniziato | Deutsche Bank | Buy |
2023-07-24 | Aggiornamento | Goldman | Neutral → Buy |
2023-03-31 | Iniziato | Mizuho | Buy |
2023-01-05 | Iniziato | BofA Securities | Buy |
2022-05-25 | Iniziato | Citigroup | Buy |
2022-04-01 | Downgrade | Goldman | Buy → Neutral |
Mostra tutto
Amylyx Pharmaceuticals Inc Borsa (AMLX) Ultime notizie
What analysts say about Amylyx Pharmaceuticals Inc. stockDouble-digit growth - Autocar Professional
Is Amylyx Pharmaceuticals Inc. a good long term investmentFree Buy/Sell Signal Notifications - Autocar Professional
Hypoglycemia Clinical, Companies, Therapeutic Assessment, - openPR.com
What drives Amylyx Pharmaceuticals Inc. stock priceHigh-return market picks - jammulinksnews.com
Published on: 2025-07-22 15:57:30 - jammulinksnews.com
autocarpro> 2025> What drives Amylyx Pharmaceuticals Inc. stock priceRobust financial gains - Autocar Professional
Amylyx Pharmaceuticals: High-Risk, High-Reward Biotech Play with Game-Changing Pipeline Catalysts in 2026 - AInvest
Amylyx Pharmaceuticals: A High-Risk Pipeline With Strong Upside Potential (NASDAQ:AMLX) - Seeking Alpha
Promising Potential of Amylyx Pharmaceuticals’ Avexitide Program Drives Buy Rating - TipRanks
How Amylyx Pharmaceuticals Inc. stock performs during market volatilityFree Exclusive Group - Newser
What makes Amylyx Pharmaceuticals Inc. stock price move sharplyVolume Spike Monitors - Newser
Amylyx Pharmaceuticals Shares Promising Avexitide Data for Post-Bariatric Hypoglycemia at ENDO 2025, Phase 3 Enrollment Nears Completion - Insider Monkey
Why Amylyx Pharmaceuticals Inc. stock attracts strong analyst attentionFree Capital Growth Strategies - Newser
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating - GlobeNewswire
AMYLYX ALERT: Bragar Eagel & Squire, P.C. is Investigating Amylyx Pharmaceuticals, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm - GlobeNewswire Inc.
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential - Investing.com Nigeria
TD Cowen reiterates Buy rating on Amylyx stock, cites avexitide potential By Investing.com - Investing.com South Africa
Amylyx Drug Slashes Sugar Spikes Post-Weight Loss SurgeryAmylyx Pharmaceuticals (NASDAQ:AMLX) - Benzinga
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event By Investing.com - Investing.com South Africa
Amylyx presents new exploratory analyses from avexitide trials for PBH - Yahoo Finance
Citi maintains Buy rating on Amylyx Pharmaceuticals stock after KOL event - Investing.com Nigeria
Amylyx Pharmaceuticals Reports Results of Phase 2b Post-Bariatric Hypoglycemia Clinical Trial - MarketScreener
Amylyx Pharma Gains Retail Buzz As Once-Daily Pill Cuts Severe Blood Sugar Crashes In Mid-Stage Trial - NewsBreak: Local News & Alerts
Transcript : Amylyx Pharmaceuticals, Inc.Special Call - MarketScreener
Amylyx Pharmaceuticals Presents New Exploratory Analyses from Phase 2 and Phase 2b Clinical Trials of Avexitide in Post-Bariatric Hypoglycemia at ENDO 2025 - BioSpace
Amylyx Pharmaceuticals (NASDAQ:AMLX) Upgraded at The Goldman Sachs Group - MarketBeat
Breakthrough Drug Cuts Dangerous Post-Bariatric Surgery Events by 64%: Phase 2 Trial Results Revealed - Stock Titan
Amylyx Pharmaceuticals (NASDAQ:AMLX) Raised to “Buy” at The Goldman Sachs Group - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Amylyx Pharmaceuticals, Inc. (AMLX) And Encourages Shareholders to Connect - ACCESS Newswire
Promising Potential of Avexitide Drives Amylyx Pharmaceuticals’ Growth Prospects - TipRanks
Amylyx Pharmaceuticals Inc Azioni (AMLX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):